FDA-Approved Treatment (unspecified)
Oncology
ApprovedCommercial
Key Facts
About Nuvation Bio
Nuvation Bio is a publicly traded, commercial-stage oncology company with a mission to develop new generations of cancer medicines that address drug resistance and limited efficacy of current therapies. Founded by Dr. David Hung, the architect behind blockbuster prostate cancer drug XTANDI, the company leverages a patient-first mindset and a deep pipeline of novel therapeutic candidates targeting critical cancer pathways. With offices in New York, San Francisco, Boston, and Shanghai, Nuvation Bio is positioned to tackle some of the toughest challenges in cancer treatment.
View full company profileTherapeutic Areas
Other Oncology Drugs
| Drug | Company | Phase |
|---|---|---|
| Mvasi (bevacizumab biosimilar) | Viatris | Approved |
| DRL-17822 | Dr. Reddy's Laboratories | Phase 2 |
| Biosimilar Portfolio | Zydus Lifesciences | Various |
| therascreen Solid Tumor | Qiagen | Commercial |
| GBR 830 | Glenmark Pharmaceuticals | Phase 1 |
| Bevacizumab Biosimilar | Glenmark Pharmaceuticals | Approved |
| Biosimilar (Bevacizumab) | Ipca Laboratories | Development |
| LockBody Platform Assets | Centessa Pharmaceuticals | Pre-clinical |
| Everolimus | Amneal Pharmaceuticals | Approved |
| Lenalidomide (Revlimid generic) | Amneal Pharmaceuticals | Approved |
| Alymsys (bevacizumab-maly) | Amneal Pharmaceuticals | Approved |
| Pemrydi RTU | Amneal Pharmaceuticals | Approved |